Collplant Biotechnologies Ltd (CLGN) - Total Liabilities
Based on the latest financial reports, Collplant Biotechnologies Ltd (CLGN) has total liabilities worth $4.78 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CLGN cash flow metrics to assess how effectively this company generates cash.
Collplant Biotechnologies Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Collplant Biotechnologies Ltd's total liabilities have evolved over time, based on quarterly financial data. Check CLGN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Collplant Biotechnologies Ltd Competitors by Total Liabilities
The table below lists competitors of Collplant Biotechnologies Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Redsense Medical AB
ST:REDS
|
Sweden | Skr3.89 Million |
|
Envy Technologies Indonesia Tbk PT
JK:ENVY
|
Indonesia | Rp68.24 Billion |
|
Dominion Minerals Ltd
AU:DLM
|
Australia | AU$325.75K |
|
Veganz Group AG
F:VEZ
|
Germany | €20.64 Million |
|
Kingman Minerals Ltd
V:KGS
|
Canada | CA$599.66K |
|
West Cobar Metals Ltd
AU:WC1
|
Australia | AU$369.59K |
|
Bryah Resources Ltd
AU:BYH
|
Australia | AU$410.93K |
|
HUIJING HLDG.CO.LTD HD-01
F:3XU
|
Germany | €10.48 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Collplant Biotechnologies Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CLGN market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Collplant Biotechnologies Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Collplant Biotechnologies Ltd (2012–2024)
The table below shows the annual total liabilities of Collplant Biotechnologies Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.25 Million | -9.35% |
| 2023-12-31 | $5.79 Million | +5.45% |
| 2022-12-31 | $5.49 Million | -10.09% |
| 2021-12-31 | $6.10 Million | -4.10% |
| 2020-12-31 | $6.36 Million | -4.50% |
| 2019-12-31 | $6.66 Million | +55.35% |
| 2018-12-31 | $4.29 Million | -21.37% |
| 2017-12-31 | $5.46 Million | +126.31% |
| 2016-12-31 | $2.41 Million | +150.95% |
| 2015-12-31 | $960.64K | +41.32% |
| 2014-12-31 | $679.77K | -25.77% |
| 2013-12-31 | $915.72K | +14.77% |
| 2012-12-31 | $797.87K | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more